Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ZNTL 
Zentalis Pharmaceuticals Llc (ZNTL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ZNTL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -67.04% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 99.82M USD | Price to earnings Ratio - | 1Y Target Price 6.27 |
Price to earnings Ratio - | 1Y Target Price 6.27 | ||
Volume (30-day avg) 937950 | Beta 1.75 | 52 Weeks Range 1.36 - 16.21 | Updated Date 04/1/2025 |
52 Weeks Range 1.36 - 16.21 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.33 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -245.96% | Operating Margin (TTM) -171.65% |
Management Effectiveness
Return on Assets (TTM) -23.86% | Return on Equity (TTM) -42.83% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -217685760 | Price to Sales(TTM) 1.48 |
Enterprise Value -217685760 | Price to Sales(TTM) 1.48 | ||
Enterprise Value to Revenue 7.77 | Enterprise Value to EBITDA -2.31 | Shares Outstanding 71811504 | Shares Floating 45013608 |
Shares Outstanding 71811504 | Shares Floating 45013608 | ||
Percent Insiders 15.46 | Percent Institutions 92.9 |
Analyst Ratings
Rating 3.82 | Target Price 9.5 | Buy 1 | Strong Buy 4 |
Buy 1 | Strong Buy 4 | ||
Hold 6 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Zentalis Pharmaceuticals Llc
Company Overview
History and Background
Zentalis Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancer. Founded in 2014, Zentalis has focused on developing differentiated therapies for cancers with significant unmet need.
Core Business Areas
- Small Molecule Drug Development: Focuses on discovering and developing small molecule therapeutics for cancer.
Leadership and Structure
The leadership team includes seasoned executives with experience in drug discovery, development, and commercialization. The company is structured around research and development, clinical operations, and business development functions.
Top Products and Market Share
Key Offerings
- ZN-c3: A WEE1 inhibitor currently in clinical trials for various cancers. Competitors in WEE1 inhibition include companies like Repare Therapeutics (RPTX).
- ZN-d6: A selective oral SERD (selective estrogen receptor degrader) being investigated for the treatment of ER+/HER2- breast cancer. Competitors in this space include Radius Health (RDUS) and Menarini Group's elacestrant.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. Oncology remains a key area of focus.
Positioning
Zentalis is positioned as an innovator in developing targeted therapies for cancer, focusing on differentiated approaches to address unmet needs.
Total Addressable Market (TAM)
The global oncology market is expected to reach hundreds of billions of dollars. Zentalis is positioned to capture a portion of this TAM through its innovative pipeline.
Upturn SWOT Analysis
Strengths
- Strong pipeline of novel oncology candidates
- Experienced management team
- Proprietary drug discovery platform
Weaknesses
- Reliance on clinical trial success
- High cash burn rate
- Dependence on key personnel
Opportunities
- Potential for strategic collaborations and partnerships
- Expansion of pipeline into new indications
- Advancements in precision medicine
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
Competitors and Market Share
Key Competitors
- RPTX
- RDUS
- MRK
- AZN
- BMY
Competitive Landscape
Zentalis faces competition from established pharmaceutical companies with greater resources and broader portfolios. Its advantage lies in its targeted therapies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Zentalis has focused on pipeline development and clinical trial advancement.
Future Projections: Analysts project revenue growth upon successful drug approvals, but also anticipate continued high R&D expenses.
Recent Initiatives: Recent initiatives include advancing clinical trials for ZN-c3 and ZN-d6 and pursuing strategic partnerships.
Summary
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company with a promising pipeline of oncology candidates, with novel approaches to address significant unmet needs in the oncology space. Its success hinges on successful clinical trial outcomes and regulatory approvals. The company needs to secure partnerships and manage cash flow to offset high R&D expenses. Competitive pressures from established players remain a significant challenge for the company's growth trajectory.
Similar Companies
AZN
AstraZeneca PLC ADR
AZN
AstraZeneca PLC ADR
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
MRK
Merck & Company Inc
MRK
Merck & Company Inc
RDUS
Schnitzer Steel Industries Inc
RDUS
Schnitzer Steel Industries Inc
RPTX
Repare Therapeutics Inc
RPTX
Repare Therapeutics Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data and market share estimates are based on available information and may not be exact.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zentalis Pharmaceuticals Llc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2020-04-03 | CEO, President & Director Ms. Julie M. Eastland M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 166 | Website https://zentalis.com |
Full time employees 166 | Website https://zentalis.com | ||
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.